CMS Finalizes TAVR Coverage Rules as Edwards Adds PASCAL Ace, EVOQUE Approvals
EW sits 38% above its 52-week low of $74.66 on elevated volume (2.2× avg).
Summary
CMS finalized updated U.S. TAVR coverage rules, which Edwards says could expand timely patient access and reinforce multidisciplinary heart teams — a policy tailwind for its largest franchise. The roundup also confirms FDA approval of PASCAL Precision for tricuspid repair and PASCAL Ace for mitral repair, plus U.S. and European approval of EVOQUE for transjugular access, extending the TMTT portfolio that grew 44% in Q3. These come on top of Q3 sales of $1.72 billion (up 10.5%) and adjusted EPS of $0.80 (up 19%), with full-year guidance raised, and PROGRESS trial data showing TAVR beat clinical surveillance in moderate aortic stenosis. Truist upgraded the stock to Buy with a $113 target. The stock is trading near its 52-week high, so the incremental approvals and CMS clarity support the current multiple rather than reset it.
At the time of this announcement, EW was trading at $103.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $57.3B. The 52-week trading range was $74.66 to $100.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.